Epigenomics AG

  • WKN: A11QW5
  • ISIN: DE000A11QW50
  • Land: Deutschland

Nachricht vom 31.08.2020 | 07:34

Epigenomics AG: CMS Still Actively Working on Proposed Decision Memo with Goal to Publish As Soon As Possible

DGAP-News: Epigenomics AG / Key word(s): Miscellaneous
31.08.2020 / 07:34
The issuer is solely responsible for the content of this announcement.

CMS Still Actively Working on Proposed Decision Memo with Goal to Publish As Soon As Possible

Berlin (Germany) and San Diego, CA (USA), August 31, 2020 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that the Centers for Medicare & Medicaid Services (CMS) did not issue the proposed decision memo for its National Coverage Analysis (NCA) for Screening for Colorectal Cancer with Blood-Based Biomarker Tests by the statutory due date of August 28, 2020. CMS is actively working on the decision, and its goal is to publish the decision as soon as possible.

"While we are disappointed CMS did not meet its statutory timeline, we recognize the agency's resources are stretched because of the pandemic," said Greg Hamilton CEO of Epigenomics. "We remain confident that CMS will issue a positive proposed decision based upon the clinical evidence and are hopeful the agency will publish it as quickly as possible."
 

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon(R), is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epi proLung(R), a blood-based test for lung cancer detection, and HCCBloodTest, a blood-based test for liver cancer detection in cirrohtic patients, have received CE mark in Europe.

For more information, visit www.epigenomics.com.
 

Contact:
Company

Epigenomics AG, Geneststrasse 5, 10829 Berlin,
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, E-Mail: contact@epigenomics.com

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, E-Mail: ir@epigenomics.com

 

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

 



31.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

ESG-Whitepaper im Fokus

The Corporate ESG Guide: A 360 view on the current landscape and trends

Die ESG-Kriterien (Environmental, Social and Governance) werden auch für Emittenten immer wichtiger, wenn sie für Investoren attraktiv bleiben wollen. In dem Whitepaper “The Corporate ESG Guide: A 360 view on the current landscape and trends” beantworten die Experten von Investor Update grundlegende Fragen von Emittenten. Außerdem kommen Vermögensverwalter, Unternehmensberater Manager und ESG-Ratingagenturen zu wichtigen ESG-Themen zu Wort.

GBC-Fokusbox

"GBC Best of m:access 2020": Neue vielversprechende Auswahl

Unsere letztjährige „GBC Best of m:access“-Auswahl hat sich mit einer Performance von über 50 % überdurchschnittlich stark entwickelt und alle relevanten Indizes hinter sich gelassen. Im Rahmen der vorliegenden aktualisierten Studie präsentieren wir Ihnen eine in Teilen neu zusammengesetzte Selektion, die weiterhin 15 Unternehmen umfasst. Die aktuellen Einschätzungen zu den Einzeltiteln und auch weitere Informationen zur Entwicklung des m:access sind in der vollständigen Studie „GBC Best of m:access 2020“ enthalten.

News im Fokus

Vonovia SE: Vonovia kauft 1.000 Wohnungen in Kiel (News mit Zusatzmaterial)

02. Dezember 2020, 18:01

Aktueller Webcast

Adler Group S.A.

Neunmonats-
Investor Call
Q3 2020

30. November 2020

Aktuelle Research-Studie

ERWE Immobilien AG

Original-Research: ERWE Immobilien AG (von GSC Research GmbH): Halten

03. Dezember 2020